


The number of individual cases identified in EudraVigilance for COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) is 539,132 (up to 03/12/2022)


Number of individual cases by Age Group

Age Group	Cases	%
Not Specified	36,789	6.8%
0-1 Month	310	0.1%
2 Months - 2 Years	337	0.1%
3-11 Years	286	0.1%
12-17 Years	315	0.1%
18-64 Years	420,179	77.9%
65-85 Years	77,747	14.4%
More than 85 Years	3,169	0.6%
Total	539,132	100.0%




Number of individual cases by Sex

Sex	Cases	%
Female	376,491	69.8%
Male	146,550	27.2%
Not Specified	16,091	3.0%
Total	539,132	100.0%




Number of individual cases by Geographic Origin (EEA/Non-EEA)

Occurrence Country EEA/Non EEA	Cases	%
European Economic Area	332,552	61.7%
Non European Economic Area	206,580	38.3%
Not Specified	0	
Total	539,132	100.0%



Reporter Group	Cases	%
Healthcare Professional	171,987	31.9%
Non Healthcare Professional	367,145	68.1%
Not Specified	0	
Total	539,132	100.0%


Number of individual cases by Reporter Group



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu

Number of individual cases identified in EudraVigilance received over the last 12 months and overall for COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) (up to 03/12/2022)



Number of Individual Cases received over time



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu

Number of individual cases identified in EudraVigilance in EEA countries for COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19) (up to 03/12/2022)

The country is not displayed if the number of cases is less or equal to 3 for that country



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu

Choose how you want to see the number of individual cases identified in EudraVigilance for **COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)** (up to 03/12/2022)



For the interpretation of the results, please refer to the key considerations at www.adrreports.eu